Inspire Medical Systems Inc (NYSE:INSP) reported Q3 earnings with sales of $153.3 million, up 40% Y/Y, beating the consensus of $154.45 million. The company increased its FY23 revenue guidance to $608 million-$612 million. Mizuho Securities noted a temporary revenue shortfall due to a discontinued pilot program. Despite concerns over potential near-term impacts on its growth trajectory and competition from GLP-1 therapies, analysts view the current dip in share price as an investment opportunity. INSP shares are down 18.90% at $131.20.